The in vivo antitumor test showed that KGPs could effectively protect the thymus and spleen of tumor-bearing mice from solid tumors and enhance the immunoregulatory capability of CD4+ T cells and the cytotoxic effects of CD8+ T cells and NK cells, finally leading to the inhibitory effects on H22 solid tumors. This evidence concerns the gene CD8A and neoplasm.